Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib

Authors

Scott R. Goldsmith, Washington University School of Medicine in St. Louis
Sana Saif Ur Rehman, Washington University School of Medicine in St. Louis
Cara L. Shirai, Washington University School of Medicine in St. Louis
Kiran Vij, Washington University School of Medicine in St. Louis
John F. DiPersio, Washington University School of Medicine in St. Louis

Journal

Blood Advances

Publication Date

2019

Volume

3

Issue

23

First Page

4131

Last Page

4135

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019000898.

Rights and Permissions

Scott R. Goldsmith, Sana Saif Ur Rehman, Cara L. Shirai, Kiran Vij, John F. DiPersio; Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Adv 2019; 3 (23): 4131–4135. doi: https://doi.org/10.1182/bloodadvances.2019000898

Recommended Citation

Goldsmith, Scott R.; Saif Ur Rehman, Sana; Shirai, Cara L.; Vij, Kiran; and DiPersio, John F., "Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib." Blood Advances. 3, 23. 4131 - 4135. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8601